South Korean biopharmaceutical firm Medytox has secured an exclusive supply agreement with Greek medical device and cosmetics distributor Asklipios Medical Group (AMG) for its neuroderma cosmetic brand NEURADERM, marking a strategic push into the European market. The deal, announced on May 8, expands NEURADERM's footprint to seven European countries including Greece, Italy, Spain, and France, following earlier entries into Japan, Vietnam, Indonesia, and Hong Kong. For overseas buyers and distributors, this signals Medytox's growing commitment to building a direct European distribution channel for its premium derma-cosmetic line, potentially opening new sourcing opportunities for clinic and retail partners.
Deal details and market expansion
Under the exclusive agreement, AMG will distribute NEURADERM products across Greece, Italy, Spain, France, and three other European nations. Medytox plans to leverage AMG's established distribution network to enter multiple online and offline sales channels, gradually strengthening its presence in the European aesthetic market. The partnership follows AMG's successful showcase of NEURADERM at Beauty Macedonia 2026, Greece's largest beauty expo held in May, where the lineup received positive feedback from global buyers and consumers.
Product portfolio and brand positioning
NEURADERM is a neuroderma cosmetic brand developed from over 20 years of neuroscience and dermatology R&D by Medytox. The brand focuses on improving skin quality through wrinkle reduction, elasticity enhancement, and barrier strengthening. Key products include the NEURADERM Core Time Ampoule, Core Time Synergy Essence, and Derma Cream. The company recently launched a renewed version of its Deep Calming Mist, indicating ongoing product development efforts.
Strategic significance for European buyers
For European importers, distributors, and clinic buyers, this exclusive deal provides a direct channel to source a Korean derma-cosmetic brand backed by established neurotoxin expertise. AMG's existing network and the positive reception at Beauty Macedonia suggest potential for market acceptance. Buyers should monitor Medytox's European expansion strategy and AMG's distribution capabilities for potential partnership or procurement opportunities.
Sourcing context
Medytox's financial performance from 2023 to 2025 shows steady revenue and profit trends, though specific figures were not disclosed in this announcement. The company's focus on expanding NEURADERM internationally aligns with growing demand for Korean derma-cosmetic products in Europe. Distributors interested in adding a science-backed, neuroderma brand to their portfolio may consider contacting AMG or Medytox directly for wholesale terms.
Source: Read the original report | Published: June 08, 2026